Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)

Explore clinical trials studying Post-essential Thrombocythemia Myelofibrosis (Post-ET MF). Study availability and eligibility vary by location and protocol.

4 public trials 1 recruiting study

Refine in advanced search Browse all conditions

Post-essential Thrombocythemia Myelofibrosis (Post-ET MF) trial results

Recruiting

MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)

NCT07362225

Conditions: Accelerated Phase MPN, Accelerated Phase Myeloproliferative Neoplasm, Agnogenic Myeloid Metaplasia, +78 more
Locations: MPN Research Foundation Chicago, Illinois, United States

Memorial Sloan Kettering Cancer Center New York, United States

View Trial Details

Active, not recruiting

Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis

NCT07340138

Conditions: Bone Marrow Diseases, Hematologic Diseases, Hemic and Lymphatic Diseases, +5 more
Locations: Novartis Investigative Site Sapporo, Hokkaido, Japan

Novartis Investigative Site Kamogawa, Chiba, Japan

Novartis Investigative Site Chūō, Yamanashi, Japan

View Trial Details

Active, not recruiting

Extended Access of Momelotinib in Adults With Myelofibrosis

NCT03441113

Conditions: Bone Marrow Diseases, Hematologic Diseases, Hemic and Lymphatic Diseases, +6 more
Locations: GSK Investigational Site Scottsdale, Arizona, United States

GSK Investigational Site Orange, California, United States

GSK Investigational Site Stanford, California, United States

GSK Investigational Site Aurora, Colorado, United States

View all 112 locations

View Trial Details

Completed

Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF

NCT02101268

Conditions: Bone Marrow Diseases, Hematologic Diseases, Hemic and Lymphatic Diseases, +5 more
Locations: Los Angeles, California, United States

Gainesville, Florida, United States

Atlanta, Georgia, United States

Kansas City, Kansas, United States

View all 48 locations

View Trial Details

Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)

Post-essential Thrombocythemia Myelofibrosis (Post-ET MF) trial results

MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)

Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis

Extended Access of Momelotinib in Adults With Myelofibrosis

Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF

Related conditions